A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

被引：5
|
作者：
Wang-Gillam, Andrea [1 ]
Tew, William P. [2 ]
Rothenberg, Mace L. [3 ,5 ]
Dupont, Jakob [2 ]
Cooper, Wendy [3 ]
Sternas, Lars [4 ]
Buzenet, Giliane [4 ]
Sosman, Jeffrey A. [3 ]
Spriggs, David R. [2 ]
Lockhart, Albert Craig [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Sanofi Aventis Oncol, Bridgewater, NJ USA
[5] Pfizer Inc, New York, NY USA
来源：
INVESTIGATIONAL NEW DRUGS | 2012年 / 30卷 / 05期
关键词：
Phase I study; Aflibercept; Angiogenesis inhibitor; Subcutaneously administration; GROWTH-FACTOR-TRAP; ASCITES;
D O I：
10.1007/s10637-011-9753-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.
引用
收藏
页码：1958 / 1961
页数：4
相关论文
共 50 条
  • [31] A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
    Wang-Gillam, Andrea
    Arnold, Susanne M.
    Bukowski, Ronald M.
    Rothenberg, Mace L.
    Cooper, Wendy
    Wang, Kenneth K.
    Gauthier, Eric
    Lockhart, A. Craig
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 266 - 272
  • [32] Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies
    Bahleda, Rastislav
    Baker, Jackie
    Massard, Christophe
    Gadgeel, Sirish M.
    Rogers, Jane E.
    Izzedine, Hassan
    Deutsch, Eric
    Garris, Jeana L.
    Khan, Akbar
    Boelle, Emmanuelle
    Assadourian, Sylvie
    Soria, Jean-Charles
    Ajani, Jaffer A.
    ONCOLOGY, 2016, 90 (01) : 10 - 20
  • [33] Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
    Misset, JL
    Gamelin, E
    Campone, M
    Delaloge, S
    Latz, JE
    Bozec, L
    Fumoleau, P
    ANNALS OF ONCOLOGY, 2004, 15 (07) : 1123 - 1129
  • [34] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Emiliano Calvo
    Cristiana Sessa
    Guilherme Harada
    Maria de Miguel
    Carmen Kahatt
    Xarles Erik Luepke-Estefan
    Mariano Siguero
    Carlos Fernandez-Teruel
    Martin Cullell-Young
    Anastasios Stathis
    Alexander Drilon
    Investigational New Drugs, 2022, 40 : 1263 - 1273
  • [35] A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
    Andrea Wang-Gillam
    Susanne M. Arnold
    Ronald M. Bukowski
    Mace L. Rothenberg
    Wendy Cooper
    Kenneth K. Wang
    Eric Gauthier
    A. Craig Lockhart
    Investigational New Drugs, 2012, 30 : 266 - 272
  • [36] Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
    Fujisaka, Yasuhito
    Kurata, Takayasu
    Tanaka, Kaoru
    Kudo, Toshihiro
    Okamoto, Kunio
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Okamoto, Isamu
    Namiki, Masayuki
    Kitamura, Chifumi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 380 - 388
  • [37] Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
    Yasuhito Fujisaka
    Takayasu Kurata
    Kaoru Tanaka
    Toshihiro Kudo
    Kunio Okamoto
    Junji Tsurutani
    Hiroyasu Kaneda
    Isamu Okamoto
    Masayuki Namiki
    Chifumi Kitamura
    Kazuhiko Nakagawa
    Investigational New Drugs, 2015, 33 : 380 - 388
  • [38] Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors
    Yamamoto, N
    Tamura, T
    Kamiya, Y
    Ono, H
    Kondoh, H
    Shirao, K
    Matsumura, Y
    Tanigawara, Y
    Shimada, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (06) : 302 - 308
  • [39] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Calvo, Emiliano
    Sessa, Cristiana
    Harada, Guilherme
    de Miguel, Maria
    Kahatt, Carmen
    Luepke-Estefan, Xarles Erik
    Siguero, Mariano
    Fernandez-Teruel, Carlos
    Cullell-Young, Martin
    Stathis, Anastasios
    Drilon, Alexander
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1263 - 1273
  • [40] PHASE-I STUDY OF RP 49532A, A NEW PROTEIN-SYNTHESIS INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY SOLID TUMORS
    CATIMEL, G
    COQUARD, R
    GUASTALLA, JP
    MERROUCHE, Y
    LEBAIL, N
    ALAKL, MK
    DUMORTIER, A
    FOY, M
    CLAVEL, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) : 246 - 248
12345